Nectar Lifesciences Limited

NSEI:NECLIFE 株式レポート

時価総額:₹9.2b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Nectar Lifesciences バランスシートの健全性

財務の健全性 基準チェック /46

Nectar Lifesciencesの総株主資本は₹10.7B 、総負債は₹6.4Bで、負債比率は59.4%となります。総資産と総負債はそれぞれ₹21.9Bと₹11.2Bです。 Nectar Lifesciencesの EBIT は₹923.8Mで、利息カバレッジ比率1.1です。現金および短期投資は₹203.0Mです。

主要情報

59.4%

負債資本比率

₹6.36b

負債

インタレスト・カバレッジ・レシオ1.2x
現金₹203.01m
エクイティ₹10.69b
負債合計₹11.22b
総資産₹21.91b

財務の健全性に関する最新情報

Recent updates

Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Aug 22
Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Jul 27
Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Feb 19
Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Dec 22
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Jun 16
Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Jun 21
Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Jul 29
Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Feb 25
Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

Jan 21
Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Nov 02
Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Sep 07
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

Aug 09
If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

Aug 09
The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

Jul 13
What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

財務状況分析

短期負債: NECLIFEの 短期資産 ( ₹12.8B ) が 短期負債 ( ₹9.7B ) を超えています。

長期負債: NECLIFEの短期資産 ( ₹12.8B ) が 長期負債 ( ₹1.5B ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: NECLIFEの 純負債対資本比率 ( 57.5% ) は 高い と見なされます。

負債の削減: NECLIFEの負債対資本比率は、過去 5 年間で81.7%から59.4%に減少しました。

債務返済能力: NECLIFEの負債は 営業キャッシュフロー によって 十分にカバー されています ( 35.4% )。

インタレストカバレッジ: NECLIFEの負債に対する 利息支払いEBIT ( 1.1 x coverage) によって 十分にカバーされていません


貸借対照表


健全な企業の発掘